Status:
COMPLETED
A Study of LY3502970 in Participants With Type 2 Diabetes
Lead Sponsor:
Eli Lilly and Company
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to learn more about the safety of LY3502970 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3502970 is in the bl...
Eligibility Criteria
Inclusion
- Have type 2 diabetes mellitus (T2DM) for at least 6 months
- Have a glycated hemoglobin (HbA1c) value at screening of greater than or equal to (≥)7.0 percent (%) and less than or equal to (≤)10.5% and are treated with diet and exercise alone or a stable dose of metformin for at least 3 months prior to screening
- Have a body weight of ≥45 kilograms (kg) and have a body mass index of 18.5 to 45 kilograms per square meter (kg/m²), inclusive
- Have had a stable body weight for the 3 months prior to screening (less than \[\<\]5% body weight change)
- Males and females (not considered woman of childbearing potential)
Exclusion
- Have type 1 diabetes mellitus, latent autoimmune diabetes in adults or have had an episode of ketoacidosis or hyperosmolar state requiring hospitalization in the 6 months prior to screening
- Have had any of the following within the past 6 months prior to screening: myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack, cerebrovascular accident or decompensated congestive heart failure, or currently have New York Health Association Class III or IV heart failure
- Show evidence of hepatitis B, and/or positive hepatitis B surface antigen
- Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
- Any glucose-lowering medications other than metformin within 3 months prior to screening
Key Trial Info
Start Date :
October 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 12 2021
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT04426474
Start Date
October 8 2020
End Date
July 12 2021
Last Update
July 27 2021
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Pharmacology of Miami
Hialeah, Florida, United States, 33014
2
Hassman Research Institute
Marlton, New Jersey, United States, 08053
3
Midwest Clinical Research Unit
Dayton, Ohio, United States, 45417
4
Endeavor Clinical Trials
San Antonio, Texas, United States, 78229